NASDAQ:ACHV - Achieve Life Sciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $50.33
  • Forecasted Upside: 551.99 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$7.72
▼ -0.55 (-6.65%)
1 month | 3 months | 12 months
Get New Achieve Life Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ACHV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ACHV

Average Price Target: $50.33
▲ +551.99% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Achieve Life Sciences in the last 3 months. The average price target is $50.33, with a high forecast of $100.00 and a low forecast of $21.00. The average price target represents a 551.99% upside from the last price of $7.72.

Buy

The current consensus among 4 contributing investment analysts is to buy stock in Achieve Life Sciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/29/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/14/2021Maxim GroupInitiated CoverageBuy$21.00Low
4/6/2021HC WainwrightReiterated RatingBuyLow
3/12/2021Maxim GroupReiterated RatingBuy$21.00High
9/18/2020Maxim GroupInitiated CoverageBuy$21.00High
9/17/2020Lake Street CapitalInitiated CoverageBuy$30.00High
8/21/2020Maxim GroupReiterated RatingBuyHigh
8/7/2020LADENBURG THALM/SH SHReiterated RatingBuy$100.00Low
6/30/2020Maxim GroupReiterated RatingBuy$40.00High
5/19/2020Maxim GroupInitiated CoverageBuy$40.00Low
2/25/2020HC WainwrightInitiated CoverageBuy$40.00High
10/1/2019Maxim GroupReiterated RatingBuy$120.00Low
9/24/2019Maxim GroupReiterated RatingBuy$120.00High
8/9/2019Maxim GroupSet Price TargetBuy$120.00High
8/9/2019LADENBURG THALM/SH SHReiterated RatingBuy$400.00High
7/24/2019Maxim GroupReiterated RatingBuy$120.00Low
6/21/2019Maxim GroupSet Price TargetBuy$120.00Low
6/14/2019Maxim GroupInitiated CoverageBuy$120.00High
6/11/2019LADENBURG THALM/SH SHSet Price TargetPositive ➝ Buy$240.00 ➝ $400.00High
8/20/2018LADENBURG THALM/SH SHInitiated CoverageBuy$240.00High
(Data available from 6/21/2016 forward)
Achieve Life Sciences logo
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in the United States and internationally. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
Read More

Today's Range

Now: $7.72
Low: $7.72
High: $8.38

50 Day Range

MA: $9.44
Low: $7.31
High: $11.50

52 Week Range

Now: $7.72
Low: $6.85
High: $18.26

Volume

396,200 shs

Average Volume

220,525 shs

Market Capitalization

$47.59 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.39

Frequently Asked Questions

What sell-side analysts currently cover shares of Achieve Life Sciences?

The following Wall Street sell-side analysts have issued reports on Achieve Life Sciences in the last year: HC Wainwright, LADENBURG THALM/SH SH, Lake Street Capital, and Maxim Group.
View the latest analyst ratings for ACHV.

What is the current price target for Achieve Life Sciences?

3 Wall Street analysts have set twelve-month price targets for Achieve Life Sciences in the last year. Their average twelve-month price target is $50.33, suggesting a possible upside of 552.0%. LADENBURG THALM/SH SH has the highest price target set, predicting ACHV will reach $100.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $21.00 for Achieve Life Sciences in the next year.
View the latest price targets for ACHV.

What is the current consensus analyst rating for Achieve Life Sciences?

Achieve Life Sciences currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ACHV will outperform the market and that investors should add to their positions of Achieve Life Sciences.
View the latest ratings for ACHV.

What other companies compete with Achieve Life Sciences?

How do I contact Achieve Life Sciences' investor relations team?

Achieve Life Sciences' physical mailing address is 1040 WEST GEORGIA STREET SUITE 1030, VANCOUVER BC, V6E 4H1. The biopharmaceutical company's listed phone number is 604-210-2217 and its investor relations email address is [email protected] The official website for Achieve Life Sciences is achievelifesciences.com.